Abstract: The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of a TLR-4 mediated disease or condition comprising administering an aptamer of the present disclosure to a subject in need thereof, alone or combination with other pharmacological and/or surgical interventions. In a particular aspect, the aptamers of the present disclosure are administered before, during, or after pharmacological and/or surgical interventions (e.g., thrombolysis such as thrombectomy) or any combination thereof, for the treatment of ischemic (e.g., myocardial infarction or ischemic stroke), hemorrhagic (e.g., hemorrhagic stroke or hemorrhagic transformation), or neurodegenerative (e.g., multiple sclerosis) diseases or conditions. The disclosure also provides specific doses and dosage regimes.

Abstract: Use of FGF-2 and Anosmin-1 proteins to predict the histopathology of the lesions of a subject with a demyelinating disease of the central nervous system (CNS) by detecting the amount of such proteins in a sample of isolated biological fluid. Furthermore, the present invention relates to a method for the understanding of the histopathological features of the lesions of a subject with a CNS demyelinating disease a kit to carry out this method. Preferably, the CNS demyelinating disease is multiple sclerosis, and the biological fluid is cerebrospinal fluid (CSF).